THURSDAY, Sept. 22, 2022 (HealthDay News) — High coffee consumption is associated with longer prostate cancer survival (PCSS) for some subgroups of men, including those with CYP1A2 The AA genotype, according to a study published online on August 19 at European Urology Oncology.
Justin R. Gregg, MD, of the University of Texas Anderson Cancer Center in Houston, and colleagues examined the relationship between coffee consumption, caffeine metabolism genotype, and survival using data from the PRACTICAL Consortium database of 5,727 men with prostate cancer. Cases were available data for CYP1A2 The 163C>A rs762551 single-nucleotide variant is associated with caffeine metabolism, coffee consumption, and follow-up over six months.
The researchers found that, although the results were not statistically significant, high coffee consumption appeared to be associated with longer PCSS and overall survival. High coffee consumption was associated with longer PCSS among men with clinically localized disease, with similar, but not statistically significant, results among those with advanced disease. Among men from CYP1A2 AA genotype, high coffee consumption was associated with significantly longer PCSS; no associations were seen for men with the AC/CC genotype. No association with overall survival was found in subgroup analysis.
“Future work is needed to replicate these findings, to identify specific populations (e.g., with the rapid caffeine metabolism genotype) in which coffee-based interventions or coffee consumption ‘prescriptions’ may be beneficial, and to identify mechanisms through which coffee – and caffeine-related metabolites influence prostate cancer progression,” the authors write.
One author disclosed financial ties to Bayer.